LUCD — Lucid Diagnostics Inc
NASDAQ · Healthcare · Medical Devices
$0.97
-$0.01 (-0.71%)
Lucid Diagnostics Inc (LUCD) is a medical devices company listed on NASDAQ. It is led by Lishan Aklog M.D., based in 360 Madison Avenue, New York, NY, United States, 10017, with about 72 employees. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Latest reported LUCD revenue for 2025-09-30 was $1.2M. Net income was -$10.4M. Revenue was up 4.1% from 2025-06-30 to 2025-09-30. LUCD currently screens at market cap $123.3M.
Use this LUCD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the LUCD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the LUCD SEC filings page. Lician reads the product cache first so this HTML stays unique to Lucid Diagnostics Inc even when a live quote feed is slow.
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
LUCD Key Statistics
Market Cap
$123.34M
Volume
562,169
Previous Close
$1.00
Day Range
$0.99 – $1.04
EPS
-$1.05
Revenue
$4.35M
Net Income
-$45.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+79.0%
Profit Margin
-1047.6%
Employees
72
LUCD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $4.35M | $2.43M | $377.00K | $500.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$45.53M | -$52.67M | -$56.17M | -$28.08M |
| EPS (Diluted) | -$1.05 | -$1.26 | -$1.55 | $0.00 |
Total Assets
$30.71M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$22.36M
Operating Cash Flow
-$44.14M
Free Cash Flow
$0.00
Lucid Diagnostics Inc Company Information
- Chairman & CEO
- Lishan Aklog M.D.
- Headquarters
- 360 Madison Avenue, New York, NY, United States, 10017
- Website
- www.luciddx.com
- Phone
- 917 813 1828
- IPO / Founded
- 2021-10-14
- Sector
- Healthcare
- Industry
- Medical Devices